Hannah Joseph Hospital IPO opens for subscription. GMP among key details to know

Hannah Joseph Hospital's IPO will open for subscription on Thursday, with the issue seeing a flat grey market premium, signaling muted expectations of listing gains amid a cautious broader market for SME issues. The IPO worth Rs 42 crore, is entirely a fresh issue of 60 lakh shares and is priced in a band of Rs 67 to Rs 70 per share. The issue will close on January 27, with listing on the BSE SME platform scheduled for January 30.

At the upper end of the price band, the company is valued at a pre-IPO market cap of about Rs 159 crore. Retail investors are required to apply for a minimum of 4,000 shares, translating into an investment of Rs 2.8 lakh, while the minimum application size for HNIs stands at Rs 4.2 lakh.

Hannah Joseph Hospital raised Rs 11.94 crore from anchor investors ahead of the public issue, with the anchor portion accounting for about 28% of the total shares on offer. As per market participants, the grey market premium is currently at 0%, indicating that informal market participants are not pricing in immediate listing gains.


Founded in 2011, Hannah Joseph Hospital operates a multi-specialty hospital in Madurai, Tamil Nadu. The hospital is spread across a 2-acre campus and has a capacity of 150 beds. The company focuses on key specialties including neurology, cardiology, psychiatry and trauma care, positioning itself as a regional healthcare provider catering to both critical and specialised treatments.

As of November 2025, the hospital employed 364 staff members. Its service mix spans neurosciences, cardiac sciences, orthopaedics and trauma care, supported by emergency and critical care infrastructure. The company is seeking to strengthen its offerings through the IPO proceeds, a significant portion of which will be used to establish a radiation oncology centre.

Financially, the company has reported steady growth over the past few years. For the six months ended September 2025, Hannah Joseph Hospital posted a profit after tax of Rs 5.12 crore on total income of Rs 42.75 crore. For FY25, profit stood at Rs 7.21 crore, while EBITDA margins remained healthy at over 26%.

With a flat GMP and relatively high ticket size for retail investors, investor response will hinge on confidence in regional healthcare growth and the company's ability to scale services profitably.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)